REGENXBIO (RGNX)
(Delayed Data from NSDQ)
$13.64 USD
+0.14 (1.04%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $13.50 -0.14 (-1.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
REGENXBIO Inc. [RGNX]
Reports for Purchase
Showing records 21 - 40 ( 66 total )
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - KOL Call Highlights: Diving into DMD
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Interim Ph1/2 RGX-202/DMD Data In October; Pipeline Progress; Q2 Financials
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Investor Day Takeaways; Updated Data at Medical Conferences in H2:23/Early 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
RGX-314 Transferred to AbbVie, Focus Shifts to the Rest of the Pipeline; Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Ph2 wAMD & DR Updates in H2:23; MPS I & MPS II Data at WORLDSymposium; Q4/FY22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Bridging Study Validates NAVXpress Platform; 6mo Data from SCS-RGX-314 in H2:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Ph2 ALTITUDE Update for SCS-RGX-314/DR; Pipeline Progress; Q3 Financials
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Interim wAMD Results From AAVIATE & Ph1/2a SR-RGX-314 LTFU; DR Update in Nov
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A